Evidence map›Paper›PMID 37308987›Full record

ArticleActa neuropathologica communications2023

Mass cytometric analysis of the immune cell landscape after traumatic brain injury elucidates the role of complement and complement receptors in neurologic outcomes.

Amer Toutonji, Carsten Krieg, Davis M Borucki, Mamatha Mandava, Silvia Guglietta, Stephen Tomlinson

Open access · goldAbstract read
In one paragraph

Article in Acta neuropathologica communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Exploring Molecular Pathways in Exercise-Induced Recovery from Traumatic Brain Injury.Medical science monitor : international medical journal of experimental and clinical research · 2025
    Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Amer ToutonjiCollege of Medicine, Medical University of South Carolina, Charleston, SC, 29425, USA.
Carsten KriegDepartment of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC, 29425, USA.
Davis M BoruckiDepartment of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, 29425, USA.
Mamatha MandavaImmune Deficiency Cellular Therapy Program (IDCTP), National Institutes of Health, Bethesda, USA.
Silvia GugliettaHollings Cancer Center, Charleston, SC, 29425, USA. gugliett@musc.edu.
Stephen Tomlinson *Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, 29425, USA. tomlinss@musc.edu.ORCID 0000-0002-6281-2122
Medical University of South Carolina · USNational Institutes of Health · US

Funding

The role of SMAD1 and SATB2 in colon patterningP20GM130457 · NIGMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI Hailong Zhang · 2020 to 2026
$18.7M
Role of the complement C3a receptor on immune and non immune intestinal barrier functions and microbiota in colorectal cancer developmentR01CA258882 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI GUGLIETTA, SILVIA · 2022 to 2025
$1.8M
The role of complement in chronic neuroinflammation and cognitive decline after closed head brain injuryI01RX003958 · VA · RALPH H JOHNSON VA MEDICAL CENTER · PI TOMLINSON, STEPHEN · 2023 to 2025
–
Role of complement in TBII01BX004256 · VA · RALPH H JOHNSON VA MEDICAL CENTER · PI Stephen Tomlinson · 2019 to 2026
–
BLR&D Research Career Scientist Award Application for Dr. Stephen TomlinsonIK6BX005235 · VA · RALPH H JOHNSON VA MEDICAL CENTER · PI TOMLINSON, STEPHEN · 2020 to 2024
–
Targeting complement and chronic inflammation after traumatic brain injuryI21RX002363 · VA · RALPH H JOHNSON VA MEDICAL CENTER · PI TOMLINSON, STEPHEN · 2016 to 2018
–
Novel Therapies to Improve Functional Recovery After StrokeI01RX001141 · VA · RALPH H JOHNSON VA MEDICAL CENTER · PI TOMLINSON, STEPHEN · 2014 to 2022
–
BLRD VA I01 BX004256BLRD VA IK6 BX005235NCI NIH HHS R01 CA258882NIGMS NIH HHS P20 GM130457RRD VA I01 RX001141RRD VA I01 RX003958
6 · The paper itself

Abstract

Following traumatic brain injury (TBI), a neuroinflammatory response can persist for years and contribute to the development of chronic neurological manifestations. Complement plays a central role in post-TBI neuroinflammation, and C3 opsonins and the anaphylatoxins (C3a and C5a) have been implicated in promoting secondary injury. We used single cell mass cytometry to characterize the immune cell landscape of the brain at different time points after TBI. To specifically investigate how complement shapes the post-TBI immune cell landscape, we analyzed TBI brains in the context of CR2-Crry treatment, an inhibitor of C3 activation. We analyzed 13 immune cell types, including peripheral and brain resident cells, and assessed expression of various receptors. TBI modulated the expression of phagocytic and complement receptors on both brain resident and infiltrating peripheral immune cells, and distinct functional clusters were identified within same cell populations that emerge at different phases after TBI. In particular, a CD11c+ (CR4) microglia subpopulation continued to expand over 28 days after injury, and was the only receptor to show continuous increase over time. Complement inhibition affected the abundance of brain resident immune cells in the injured hemisphere and impacted the expression of functional receptors on infiltrating cells. A role for C5a has also been indicated in models of brain injury, and we found significant upregulation of C5aR1 on many immune cell types after TBI. However, we demonstrated experimentally that while C5aR1 is involved in the infiltration of peripheral immune cells into the brain after injury, it does not alone affect histological or behavioral outcomes. However, CR2-Crry improved post-TBI outcomes and reduced resident immune cell populations, as well as complement and phagocytic receptor expression, indicating that its neuroprotective effects are mediated upstream of C5a generation, likely via modulating C3 opsonization and complement receptor expression.

Indexed as

Brain InjuriesBrain Injuries, TraumaticBrainComplement System ProteinsHumansReceptors, ComplementComplement System ProteinsReceptors, ComplementComplementComplement inhibitionMass cytometryMicrogliaNeuroinflammationTraumatic brain injury

Identifiers

PMID37308987
PMCPMC10258994
OpenAlexW4380373792

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.